These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3501618)

  • 1. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders.
    Meschengieser S; Blanco A; Woods A; Maugeri N; Fernandez J; Dupont J; Lazzari MA
    Thromb Res; 1987 Nov; 48(3):311-9. PubMed ID: 3501618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders.
    Cortellazzo S; Viero P; Buczko W; Barbui T; de Gaetano G
    Scand J Haematol; 1985 Feb; 34(2):146-51. PubMed ID: 3856312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.
    Villmow T; Kemkes-Matthes B; Matzdorff AC
    Thromb Res; 2002 Nov; 108(2-3):139-45. PubMed ID: 12590950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
    Wehmeier A; Fricke S; Scharf RE; Schneider W
    Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes.
    Castaman G; Lattuada A; Ruggeri M; Tosetto A; Mannucci PM; Rodeghiero F
    Am J Hematol; 1995 Aug; 49(4):289-93. PubMed ID: 7639273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
    Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
    Strati P; Bose P; Lyle L; Gaw K; Zhou L; Pierce SA; Huynh-Lu J; Hirsch-Ginsberg CF; Bueso-Mendoza DE; Bueso-Ramos CE; Verstovsek S
    Ann Hematol; 2017 May; 96(5):733-738. PubMed ID: 28247057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis.
    Fabris F; Casonato A; Grazia del Ben M; De Marco L; Girolami A
    Br J Haematol; 1986 May; 63(1):75-83. PubMed ID: 3085704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
    Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasminogenesis in blood of patients with chronic myeloproliferative syndromes].
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Drewniak W; Koczubik W
    Pol Arch Med Wewn; 2006 Jan; 115(1):23-8. PubMed ID: 17278781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.
    Lancellotti S; Dragani A; Ranalli P; Petrucci G; Basso M; Tartaglione R; Rocca B; De Cristofaro R
    J Thromb Haemost; 2015 Jul; 13(7):1226-37. PubMed ID: 25876231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders.
    Tatewaki W; Takahashi H; Shibata A
    Clin Lab Haematol; 1988; 10(4):417-25. PubMed ID: 3150698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.
    Budde U; Scharf RE; Franke P; Hartmann-Budde K; Dent J; Ruggeri ZM
    Blood; 1993 Sep; 82(6):1749-57. PubMed ID: 8400231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests.
    Boneu B; Nouvel C; Sie P; Caranobe C; Combes D; Laurent G; Pris J; Bierme R
    Scand J Haematol; 1980 Sep; 25(3):214-20. PubMed ID: 7466310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.